Used in the treatment of high-risk neuroblastoma, this antibody targets the GD2 antigen present on neuroblastoma cells, enabling immune-mediated destruction of tumor cells. It is administered as part of immunotherapy regimens, often in combination with cytokines like granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2), to enhance immune activation. The antibody induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), helping the body’s immune system recognize and kill cancer cells. It is typically used in the post-consolidation phase of treatment to eliminate minimal residual disease and improve survival outcomes in pediatric patients.